Dr. Robin Weltman (Dental), along with colleagues from Oregon Health & Science University School of Dentistry, and Hygeia Hospital in Athens, Greece, co-authored “Late-onset medication-related osteonecrosis of the jaw (MRONJ) 11 years after IV bisphosphonates following implant placement.” The case study concluded MRONJ, despite a C-terminal telopeptide (CTX) value traditionally considered favorable, underscores the limited predictive utility of CTX testing, and that management decisions should be guided by comprehensive clinical assessment and interdisciplinary communication rather than reliance on biochemical markers alone. The journal Clinical Advanced in Periodontics published the article in its March issue.